Agomab Therapeutics: Agomab Receives FDA Fast Track Designation for AGMB-129 in Fibrostenosing Crohn's Disease and Starts STENOVA Phase 2a Clinical Trial : vimarsana.com

Agomab Therapeutics: Agomab Receives FDA Fast Track Designation for AGMB-129 in Fibrostenosing Crohn's Disease and Starts STENOVA Phase 2a Clinical Trial

Agomab Therapeutics: Agomab Receives FDA Fast Track Designation for AGMB-129 in Fibrostenosing Crohn's Disease and Starts STENOVA Phase 2a Clinical Trial

finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Related Keywords

Canada , United States , Philippe Wiesel , Tim Knotnerus , Florian Rieder , Department Of Gastroenterology , Drug Administration , Trophic Communications , Fibrostenosing Crohn , Fast Track Designation , Track Designation , New Drug Application , Chief Medical Officer , Vice Chair Department , Cleveland Clinic , Agomab Therapeutics , Stephanie May ,